Barinthus Biotherapeutics plc ADR 2026年季度报告

FORM10-Q (MarkOne) QUARTERLYREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934Forthequarterlyperiod ended March 31, 2026ORTRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934Forthetransitionperiodfrom ________to ________CommissionFileNumber:001-40367 BARINTHUS BIOTHERAPEUTICS PLC (ExactNameofRegistrantasSpecifiedinitsCharter) England and WalesNot Applicable(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)20400 Century Blvd, Suite 210,Germantown, MD20874(Address of principal executive offices)(Zip Code)Registrant’stelephonenumber,includingareacode:443 917-0966 *American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 duringthe preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements forthe past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”in Rule 12b-2 of the Exchange Act. Accelerated filerSmaller reporting companyEmerging growth company Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YesNo As of April23, 2026, the registrant had 40,848,893 ordinary shares, nominal value £0.000025 per share, outstanding. Table of Contents PART I - FINANCIAL INFORMATION Item 1.Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosure About Market RiskItem 4.Controls and Procedures PART II - OTHER INFORMATION Item 1.Legal ProceedingsItem 1ARisk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSIGNATURES We own the registered trademark BARINTHUS in the United Kingdom ("U.K."), and we have filed applications at the U.K. IntellectualProperty Office and other intellectual properties to register trademarks for BARINTHUS, SNAP-TI, SNAP-CI and a design logo globally. Wealso own various trademark registrations and applications, and unregistered trademarks, including the registered trademark VACCITECH, andtrademarks relating to the technologies acquired as part of our acquisition of Avidea Technologies, Inc. ("Avidea") in December 2021 includingthe registered trademarks SNAPVAX and SYNTHOLYTIC. All other trade names, trademarks and service marks of other companies appearingin this Quarterly Report on Form 10-Q, or this Quarterly Report, are the property of their respective holders. Solely for convenience, thetrademarks and trade names in this Quarterly Report may be referred to without the ® and ™ symbols, but such references should not beconstrued as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do notintend to use or display other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, anyother companies. From time to time, we may use our website, our X (formerly known as Twitter) account at @Barinthusbio and our LinkedIn account atlinkedin.com/company/barinthus-bio to distribute material information about us and for complying with our disclosure obligations underRegulation FD. Our financial and other material information is routinely posted to and accessible on the Investors section of our website,available at www.barinthusbio.com. Investors are encouraged to review the Investors section of our website because we may post materialinformation on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website, ourX (formerly known as Twitter) posts and our LinkedIn posts are not incorporated into, and does not form a part of, thi